002390 (002390) Fair Value & Analysis
Healthcare · Market cap 105B KRW
Fair value as of: Jun 25, 2026
From 9 valuation models · updated 7 days ago
Fair value updated Jun 25, 2026 — revised from 95,816 KRW to 8,246 KRW (−91.4%) since Jun 24, 2026. Share price −15.9% over the past month.
Price vs Fair Value (12 months)
12‑month range 6,558 KRW – 11,902 KRW · fair‑value band 6,185 KRW – 10,308 KRW · the 6,920 KRW price screens below the 8,246 KRW fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
002390 (002390) currently trades at 6,920 KRW, while our model-based Fair Value estimate is 8,246 KRW — implying the stock looks roughly 19.2% undervalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, 002390 generated revenue of 551B KRW at a net margin of -0.6%. Revenue grew 13.0% year over year. It earns a return on equity of -1.1%. Net debt stands at 352B KRW. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
002390 reported revenue of 535B KRW in FY2025 versus 518B KRW in FY2021, a compound +0.8%/yr. Reported net income was −2.2B KRW in FY2025.
Is 002390 fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| 1276 1276 | HK$57.85 | HK$29.84 | -48% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 002390 (002390) undervalued?
What is the fair value of 002390?
What is the quality score of 002390?
What is the revenue of 002390 (002390)?
What is the net profit margin of 002390?
Does 002390 pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.